(Q37735606)

22 August 2017

1 reference

title

Effect of antipsychotic medications on glucose and lipid levels (English)

1 reference

22 August 2017

0 references

0 references

Parminder S Chaggar

1

1 reference

22 August 2017

Steven M Shaw

series ordinal

2

1 reference

22 August 2017

Simon G Williams

series ordinal

3

1 reference

22 August 2017

publication date

21 April 2010

1 reference

The Journal of Clinical Pharmacology

22 August 2017

published in

1 reference

22 August 2017

volume

51

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

631-638

1 reference

Schizophrenia and increased risks of cardiovascular disease

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Cardiovascular risk factors for people with mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Glucose abnormalities in the siblings of people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Olanzapine and haloperidol in first episode psychosis: two-year data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Euglycemic clamp study in clozapine-induced diabetic ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010368678

21 January 2018

Identifiers

DOI

10.1177/0091270010368678

1 reference

22 August 2017

1 reference